Search
Approval Granted for Baike Biology's Recombinant Varicella Zoster Vaccine (CHO Cell) Clinical Trial Application
2025-06-04 /
Read about 0 minute
Author：小编
Baike Biology, a subsidiary of Changchun High-tech Industries, has announced the approval of its clinical trial application for the recombinant varicella zoster vaccine (CHO cell) by the National Medical Products Administration. This vaccine, tailored for adults aged 40 and above, aims to bolster the body's immunity against the varicella-zoster virus, thereby effectively preventing herpes zoster. This approval signifies a significant milestone in Baike Biology's research and development endeavors in the field of varicella zoster vaccines.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
